+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07764978

Randomized Study Comparing AZD0120 CAR T-Cell Therapy Versus Continuous Standard Treatment in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Stem Cell Transplant

Led by AstraZeneca · Updated on 2026-08-14

750

Participants Needed

124

Research Sites

278 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating treatments for adults with newly diagnosed multiple myeloma NDMM who cannot undergo autologous stem cell transplant ASCT as their first therapy. This Phase III global study compares the effectiveness and safety of standard induction treatments IsaVRd and DRd followed by a single dose of AZD0120 against the same induction treatments followed by continuous therapy IsaRd and DRd. The goal is to see if adding AZD0120 improves progression-free survival and deeper disease response measured by minimal residual disease MRD negativity. Participants are assigned randomly to one of two groups. The first group receives induction with IsaVRd or DRd, then blood cell collection apheresis, possible bridging therapy, lymphodepletion with cyclophosphamide and fludarabine, and an intravenous dose of AZD0120, a dual-targeting BCMACD19 CAR T-cell biological product. The second group receives induction with IsaVRd or DRd followed by continuous treatment with IsaRd or DRd until the disease progresses or side effects become intolerable. Both groups receive other drugs like daratumumab, dexamethasone, lenalidomide, and bortezomib as part of induction or continuous therapy. During the study, participants will have regular assessments including measuring progression-free survival over up to nine years, monitoring MRD negative complete response rates at nine months, and tracking overall survival, side effects, and patient-reported outcomes. Blood samples will be collected to measure CAR-T cells and antibodies against AZD0120. The study involves ongoing monitoring of treatment effects and safety, with participation lasting up to nine years to fully evaluate long-term outcomes.

CONDITIONS

Brief Title

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here